Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 May;84(9):1150–1155. doi: 10.1054/bjoc.2001.1742

The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature

J P Sculier, L Ghisdal, T Berghmans, F Branle, J J Lafitte, F Vallot, A P Meert, F Lemaitre, E Steels, A Burniat, C Mascaux, M Paesmans, for the European Lung Cancer Working Party (ELCWP)
PMCID: PMC2363891  PMID: 11336463

Abstract

In order to clarify the role of mitomycin (MMC) in the treatment of NSCLC, we performed a systematic review of the literature and qualitatively assessed the selected studies using the ELCWP and Chalmers scales. 5 trials (202 patients) assessed the activity of MMC as single-agent chemotherapy in NSCLC. The overall response rate was 25% (95% Cl 19–31). In 10 randomized phase III trials (1769 patients), we studied the role of MMC in combination therapy. A meta-analysis, based on the available published data, failed to show any survival advantage of the MMC containing regimens (hazard ratio = 0.95; 95% Cl 0.83–1.10). Finally, 4 eligible trials (139 patients) assessed the activity of MMC regimens as salvage therapy, 3 in combination with vindesine and one with cisplatin and vinblastine. The overall response rate for the MMC-vindesine regimen was 10.5% (95% Cl 1.7–19.4). In conclusion, MMC is an active drug for NSCLC but does not improve survival when combined with other active drugs, particularly cisplatin. Its use for salvage therapy appears to be associated with marginal activity only. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: mitomycin, non-small cell lung cancer, meta-analysis, systematic review, chemotherapy

Full Text

The Full Text of this article is available as a PDF (66.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonomi P. D., Finkelstein D. M., Ruckdeschel J. C., Blum R. H., Green M. D., Mason B., Hahn R., Tormey D. C., Harris J., Comis R. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1989 Nov;7(11):1602–1613. doi: 10.1200/JCO.1989.7.11.1602. [DOI] [PubMed] [Google Scholar]
  2. Chalmers T. C., Smith H., Jr, Blackburn B., Silverman B., Schroeder B., Reitman D., Ambroz A. A method for assessing the quality of a randomized control trial. Control Clin Trials. 1981 May;2(1):31–49. doi: 10.1016/0197-2456(81)90056-8. [DOI] [PubMed] [Google Scholar]
  3. Crino L., Tonato M., Darwish S., Meacci M. L., Corgna E., Di Costanzo F., Buzzi F., Fornari G., Santi E., Ballatori E. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol. 1990;26(1):52–56. doi: 10.1007/BF02940294. [DOI] [PubMed] [Google Scholar]
  4. Crinó L., Darwish S., Corgna E., Meacci M. L., Di Costanzo F., Buzzi F., Fornari G., Santi F., Ballatori E., Luccioli L. Treatment of advanced non-small cell lung cancer (NSCLC): the "Umbria" cooperative study. Semin Oncol. 1988 Dec;15(6 Suppl 7):52–55. [PubMed] [Google Scholar]
  5. Donnadieu N., Paesmans M., Sculier J. P. Chimiothérapie des cancers bronchiques non à petites cellules. Meta-analyse de la littérature en fonction de l'extension de la maladie. Rev Mal Respir. 1991;8(2):197–204. [PubMed] [Google Scholar]
  6. Einhorn L. H., Loehrer P. J., Williams S. D., Meyers S., Gabrys T., Nattan S. R., Woodburn R., Drasga R., Songer J., Fisher W. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol. 1986 Jul;4(7):1037–1043. doi: 10.1200/JCO.1986.4.7.1037. [DOI] [PubMed] [Google Scholar]
  7. Fukuoka M., Masuda N., Furuse K., Negoro S., Takada M., Matsui K., Takifuji N., Kudoh S., Kawahara M., Ogawara M. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol. 1991 Apr;9(4):606–613. doi: 10.1200/JCO.1991.9.4.606. [DOI] [PubMed] [Google Scholar]
  8. Gandara D. R., Crowley J., Livingston R. B., Perez E. A., Taylor C. W., Weiss G., Neefe J. R., Hutchins L. F., Roach R. W., Grunberg S. M. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol. 1993 May;11(5):873–878. doi: 10.1200/JCO.1993.11.5.873. [DOI] [PubMed] [Google Scholar]
  9. Gridelli C., Airoma G., Incoronato P., Pepe R., Palazzolo G., Rossi A., Bianco A. R. Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 1992;30(3):212–214. doi: 10.1007/BF00686314. [DOI] [PubMed] [Google Scholar]
  10. Israel L., Chahinian P., Depierre A. Response of 65 measurable epidermoid bronchogenic tumors of known spontaneous doubling time to four different chemotherapeutic regimens--strategic deductions. Med Pediatr Oncol. 1975;1(2):83–93. doi: 10.1002/mpo.2950010203. [DOI] [PubMed] [Google Scholar]
  11. Kris M. G., Gralla R. J., Kelsen D. P., Casper E. S., Burke M. T., Fiore J. J., Cibas I. R., Heelan R. T. Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment. Chest. 1985 Mar;87(3):368–372. doi: 10.1378/chest.87.3.368. [DOI] [PubMed] [Google Scholar]
  12. Luedke D. W., Einhorn L., Omura G. A., Sarma P. R., Bartolucci A. A., Birch R., Greco F. A. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol. 1990 May;8(5):886–891. doi: 10.1200/JCO.1990.8.5.886. [DOI] [PubMed] [Google Scholar]
  13. Marino P., Pampallona S., Preatoni A., Cantoni A., Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest. 1994 Sep;106(3):861–865. doi: 10.1378/chest.106.3.861. [DOI] [PubMed] [Google Scholar]
  14. Marino P., Preatoni A., Cantoni A., Buccheri G. Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study. Lung Cancer. 1995 Aug;13(1):1–12. doi: 10.1016/0169-5002(95)00477-i. [DOI] [PubMed] [Google Scholar]
  15. Mascaux C., Paesmans M., Berghmans T., Branle F., Lafitte J. J., Lemaitre F., Meert A. P., Vermylen P., Sculier J. P., European Lung Cancer Working Party (ELCWP) A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000 Oct;30(1):23–36. doi: 10.1016/s0169-5002(00)00127-6. [DOI] [PubMed] [Google Scholar]
  16. Masutani M., Akusawa H., Kadota A., Ohchi Y., Takahashi N., Tanigawa S., Koya Y., Horie T. A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer. Respirology. 1996 Mar;1(1):49–54. doi: 10.1111/j.1440-1843.1996.tb00010.x. [DOI] [PubMed] [Google Scholar]
  17. Meert A. P., Berghmans T., Branle F., Lemaître F., Mascaux C., Rubesova E., Vermylen P., Paesmans M., Sculier J. P. Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment. Anticancer Res. 1999 Sep-Oct;19(5C):4379–4390. [PubMed] [Google Scholar]
  18. Mylonakis N., Tsavaris N., Bacoyiannis C., Karvounis N., Kakolyris S., Karabelis A., Beer M., Kosmidis P. A randomized prospective study of cisplatin and vinblastine versus cisplatin, vinblastine and mitomycin in advanced non-small cell lung cancer. Ann Oncol. 1992 Feb;3(2):127–130. doi: 10.1093/oxfordjournals.annonc.a058127. [DOI] [PubMed] [Google Scholar]
  19. Niell H. B., Griffin J. P., Hunter R. F., Meredith C. A., Somes G. Combination versus sequential single-agent chemotherapy in the treatment of patients with advanced non-small cell lung cancer. Med Pediatr Oncol. 1989;17(1):69–75. doi: 10.1002/mpo.2950170115. [DOI] [PubMed] [Google Scholar]
  20. Ruckdeschel J. C., Mehta C. R., Salazar O. M., Cohen M., Vogl S., Koons L. S., Lerner H. Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II. Cancer Treat Rep. 1981 Nov-Dec;65(11-12):965–972. [PubMed] [Google Scholar]
  21. Samson M. K., Comis R. L., Baker L. H., Ginsberg S., Fraile R. J., Crooke S. T. Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep. 1978 Jan;62(1):163–165. [PubMed] [Google Scholar]
  22. Sculier J. P., Klastersky J., Dumont J. P., Vandermoten G., Rocmans P., Libert P., Ravez P., Becquart D., Mommen P., Dalesio O. Combination chemotherapy with mitomycin and vindesine in advanced non-small cell lung cancer: a pilot study by the Lung Cancer Working Party (Belgium). Cancer Treat Rep. 1986 Jun;70(6):773–775. [PubMed] [Google Scholar]
  23. Shinkai T., Eguchi K., Sasaki Y., Tamura T., Ohe Y., Kojima A., Oshita F., Saijo N. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. Eur J Cancer. 1991;27(5):571–575. doi: 10.1016/0277-5379(91)90220-8. [DOI] [PubMed] [Google Scholar]
  24. Veeder M. H., Jett J. R., Su J. Q., Mailliard J. A., Foley J. F., Dalton R. J., Etzell P. S., Marschke R. F., Jr, Kardinal C. G., Maksymiuk A. W. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer. 1992 Nov 1;70(9):2281–2287. doi: 10.1002/1097-0142(19921101)70:9<2281::aid-cncr2820700912>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  25. Weick J. K., Crowley J., Natale R. B., Hom B. L., Rivkin S., Coltman C. A., Jr, Taylor S. A., Livingston R. B. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1991 Jul;9(7):1157–1162. doi: 10.1200/JCO.1991.9.7.1157. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES